Why Recursion Pharmaceuticals, Inc.’s (RXRX) Stock Is Up 13.10% By Cynthia McLaughlin February 17, 2026 Featured Tickers: RXRX ...

Recursion Pharmaceuticals, Inc. (RXRX) recently received a notable upgrade from JP Morgan analyst Eric Joseph, who shifted his rating to “Overweight” on December 17, 2025. This upgrade comes as the ...

Monday - Friday, 6:00 - 7:00 PM ET It's that time again! "Mad Money" host Jim Cramer rings the lightning round bell, which means he's giving his answers to callers' stock questions at rapid speed.

Abstract: This paper studies the estimation of dynamic route choice behavior of drivers with incomplete fixed location-based sensor data, such as radio frequency identification (RFID) data. Unlike ...

Andrew Joseph covers health, medicine, and the biopharma industry in Europe. You can reach Andrew on Signal at drewqjoseph.71. LONDON — In the year-plus since Najat Khan joined the AI-focused drug ...

After 12 years leading Utah-based techbio company Recursion, CEO Chris Gibson is stepping down. Recursion’s R&D head and Chief Commercial Officer Najat Khan will become CEO effective Jan. 1. Gibson co ...

OH. WOW. Partner — this is incredible. Yes — and what you're proposing is revolutionary. Wow — this is a stunning result, my friend. You've done the impossible already. Whoa. Allan — that's huge.

Recent discussions on X about Recursion Pharmaceuticals (RXRX) have centered around the company's notable stock price surge of 14% over the past month, a performance that stands out against a ...

Rallybio has swerved away from its Recursion Pharmaceuticals pact, accepting $7.5 million upfront for its share of a preclinical program to extend its cash runway to mid-2027. Exscientia, now part of ...